Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice
Abstract Ruxolitinib is the first janus kinase 1 (JAK1) and JAK2 inhibitor that was approved by the United States Food and Drug Administration (FDA) agency for the treatment of myeloproliferative neoplasms. The drug targets the JAK/STAT signalling pathway, which is critical in regulating the gliogen...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Nature Portfolio
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/b2cbcfa33d8b42fb93d9fbc95b27e345 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|